（原标题：科伦药业：控股子公司抗PD-L1塔戈利单抗获批上市） 证券时报e公司讯，科伦药业(002422)1月1日晚间公告，公司控股子公司四川科伦博泰生物医药股份有限公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)的创新人源化单克隆抗体(简称“单抗”)塔戈利单抗(前称KL-A167)(科泰莱®)已获国家药监局批准于中国上市。

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

【导读】黑色素瘤是一种恶性皮肤肿瘤，尤其是无法切除或已经转移的病例，治疗难度较大。12月24日，中南大学周文虎教授研究团队在期刊《Advanced Science》上发表了研究论文，题为“Co-Delivery of aPD-L1 and CD73 ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Solid Tumor.

Anglo-US biotech Ottimo Pharma has completed a big early-stage biotech financing, raising $140 million for its PD-1 and VEGF ...

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Gastrointestinal Tract Cancer.

INR:0738. play microgaming slots R&D Daily: AstraZeneca's PD-L1 inhibitor receives priority review, reducing the number of treatments by half Phase 3 clini ...